Login to Your Account



Vertex Acquires ViroChem in $377M Cash-Stock Deal

By Donna Young


Thursday, March 5, 2009
Vertex Pharmaceuticals Inc. is buying Canadian drugmaker ViroChem Pharma Inc., a firm specializing in hepatitis C virus (HCV) and HIV drug development, for about $377 million in a cash-and-stock deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription